RNA (Atrium Therapeutics) YoY EBITDA Growth: -176.52% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $12.07
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics YoY EBITDA Growth?

Atrium Therapeutics RNA +2.81% 12 YoY EBITDA Growth is -176.52% as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Atrium Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was -176.52%.

Atrium Therapeutics's EBITDA per Share for the three months ended in Mar. 2026 was $-1.00.

Atrium Therapeutics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics YoY EBITDA Growth Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 -108.77 -486.48

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -176.52
RNA
12GF Score
Atrium Therapeutics Inc RNA
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Atrium Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-4.469--0.762)/ | -0.762 |
=-486.48 %

Atrium Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-1.001--0.362)/ | -0.362 |
=-176.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -176.52% mean?
Atrium Therapeutics (RNA) has a YoY EBITDA Growth of -176.52% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' YoY EBITDA Growth too high?
Atrium Therapeutics' current YoY EBITDA Growth is -176.52%. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' YoY EBITDA Growth compare to KROS and PLX?
Atrium Therapeutics' YoY EBITDA Growth of -176.52% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Atrium Therapeutics and its competitors. Atrium Therapeutics's current YoY EBITDA Growth is -176.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current YoY EBITDA Growth of -176.52%. The current YoY EBITDA Growth is -176.52%. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current YoY EBITDA Growth is -176.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.07
Price